Axsome receives FDA approval for AUVELITY to treat Alzheimer's agitation

April 30, 2026 2:06 PM

Axsome Therapeutics Inc. (NASDAQ: AXSM) announced that the U.S. Food and Drug Administration has approved AUVELITY for treating agitation associated ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found